

## Prescribing of Brimonidine Tartrate 3mg/g Gel (Mirvaso®) is not supported

**Thurrock CCG and Basildon and Brentwood CCG do not support the prescribing of brimonidine tartrate 3mg/g gel (Mirvaso®) as it is considered to be a cosmetic product.**

Mirvaso® contains the active ingredient brimonidine tartrate 3mg/g and is licensed for symptomatic treatment of facial erythema of rosacea in adult patients. It achieves this by direct vasoconstriction of superficial peripheral blood vessels.

Its use is considered to be cosmetic in nature and therefore Mirvaso® is **not** recommended for prescribing.

For further information please refer to the East of England Priorities Advisory Committee guidance statement January 2015.

[PAC – Brimonidine gel](#)

Providers commissioned to provide services on behalf of Thurrock CCG and Basildon and Brentwood CCG are reminded that they are required to follow the local joint formulary and prescribing guidance, or relevant Medicines Management agreement.

<b>Position Statement No.</b>	4
<b>Title</b>	Prescribing of Brimonidine Tartrate 3mg/g Gel (Mirvaso®) is not supported
<b>References</b>	PrescQIPP Priorities Advisory Committee Jan 2015
<b>Acknowledgements</b>	Mid Essex CCG
<b>Version</b>	2 (v1 approved March 2017)
<b>Author</b>	Medicines Management Team
<b>Approved by</b>	<b>Basildon and Brentwood CCG:</b> Prescribing Subgroup, Patient Quality and Safety Committee, Board <b>Thurrock CCG:</b> Medicines Management and Safety Group, Patient Quality and Safety Committee, Transformation and Sustainability Committee, Board
<b>Date Approved</b>	March 2019
<b>Review Date</b>	March 2021